Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma
Status:
Not yet recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
ARS-1 is being developed for patients as a needleless alternative route of epinephrine
administration for the management of refractory asthma symptoms.